...
首页> 外文期刊>American Journal of Cancer Research >Long noncoding RNA ATB promotes osteosarcoma cell proliferation, migration and invasion by suppressing miR-200s
【24h】

Long noncoding RNA ATB promotes osteosarcoma cell proliferation, migration and invasion by suppressing miR-200s

机译:长非编码RNA ATB通过抑制miR-200s促进骨肉瘤细胞增殖,迁移和侵袭

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Long noncoding RNA activated by transforming growth factor-β (lncRNA-ATB) is a novel lncRNA, which is recently reported to have critical roles in carcinogenesis and progression of several cancers. However, the expression, clinical values, biological roles, and underlying molecular mechanisms of lncRNA-ATB in osteosarcoma are still known. In this study, we measured lncRNA-ATB expression in serum and osteosarcoma tissues of osteosarcoma patients, analyzed its diagnostic and prognostic values. Serum lncRNA-ATB is increased in osteosarcoma patients and could accurately discriminate osteosarcoma patients from healthy controls. LncRNA-ATB is also upregulated in osteosarcoma tissues and cell lines, and positively associated with Enneking stage, metastasis and recurrence. Increased lncRNA-ATB level indicates poor recurrence-free survival and overall survival. Functional experiments demonstrated that overexpression of lncRNA-ATB enhances osteosarcoma cells proliferation, migration, and invasion, and while depletion of lncRNA-ATB inhibits osteosarcoma cells proliferation, migration, and invasion. Mechanistically, we found that lncRNA-ATB inhibits miR-200s, and upregulates miR-200s target genes ZEB1 and ZEB2. Additionally, the roles of lncRNA-ATB on osteosarcoma cells proliferation, migration, and invasion in vitro, and osteosarcoma tumor growth in vivo are dependent on the regulation of miR-200s. Taken together, this study suggests that lncRNA-ATB may be a potential diagnostic and prognostic biomarker and a therapeutic target for osteosarcoma.
机译:通过转化生长因子-β(lncRNA-ATB)激活的长非编码RNA是一种新型的lncRNA,最近有报道称它在几种癌症的发生和发展中具有关键作用。然而,lncRNA-ATB在骨肉瘤中的表达,临床价值,生物学作用和潜在的分子机制仍然是已知的。在这项研究中,我们测量了骨肉瘤患者血清和骨肉瘤组织中lncRNA-ATB的表达,分析了其诊断和预后价值。骨肉瘤患者的血清lncRNA-ATB升高,可以准确地将骨肉瘤患者与健康对照区分开。 LncRNA-ATB在骨肉瘤组织和细胞系中也上调,并且与Enneking阶段,转移和复发呈正相关。 lncRNA-ATB水平升高表示无复发生存期和总生存期较差。功能实验表明,lncRNA-ATB的过表达增强了骨肉瘤细胞的增殖,迁移和侵袭,而lncRNA-ATB的耗尽则抑制了骨肉瘤细胞的增殖,迁移和侵袭。从机制上讲,我们发现lncRNA-ATB抑制miR-200s,并上调miR-200s目标基因ZEB1和ZEB2。此外,lncRNA-ATB在体外对骨肉瘤细胞增殖,迁移和侵袭以及体内骨肉瘤肿瘤生长的作用取决于miR-200s的调控。综上所述,这项研究表明lncRNA-ATB可能是潜在的诊断和预后生物标志物,也是骨肉瘤的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号